LUND, Sweden, March 5, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) announced today that
Andreas Johannesson has been
appointed interim CFO, effective 5 March
2020. The recruitment process for a permanent CFO is
ongoing. As previously announced, Per-Olof Schrewelius will leave
the position as CFO at Alligator.
Andreas brings to Alligator a wealth of experience from various
CFO, interim CFO and other financial positions in international
companies like Metso, Haldex, Åhléns, Fitness24Seven and orthopedic
business TeamOlmed. Andreas also has a background in strategic
consultancy within R&D and Innovation through appointments at
McKinsey and Connecta.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46-46-540-82-06
E-mail: cecilia.hofvander@alligatorbioscience.com.
The information was submitted for publication, through the
agency of the contact person set out above, at 1:45 p.m. CET on 5 March
2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company
developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes six lead clinical and
preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015,
ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics
Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai
Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-appoints-andreas-johannesson-as-interim-chief-financial-officer,c3053240
The following files are available for download:
https://mb.cision.com/Main/12681/3053240/1206313.pdf
|
Alligator Bioscience
appoints Andreas Johannesson as interim Chief Financial
Officer
|